Two independent researchers in large European studies14,15 reported an association between high doses of DAs (associated with the treatment of Parkinson’s disease) with potent 5-HT2B agonist activity and cardiac valve disease: particularly of the mitral, aortic and tricuspid valves. Here, HTR2B is linked to Parkinson disease.